Novel VLP Adjuvant based on the VesiVax system

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$287,585.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA165444-01A1
Award Id:
n/a
Agency Tracking Number:
R43CA165444
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
PA12-088
Small Business Information
9800 Connecticut Ave, Crown Point, IN, 46307-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
169940470
Principal Investigator:
DIHA FREIJE
(312) 738-0988
diha@eucliddiagnostics.com
Business Contact:
BRIKUN IGOR
(219) 644-3020
igor@eucliddiagnostics.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): Over one million prostate biopsies are performed in the US each year to diagnose approximately 200,000 cases of prostate cancer. The majority of these biopsies are performed needlessly. The overall objective of this project is to develop a secondary prostate cancer diagnostic test that can be performed on men with elevated PSA in order to identify patients in need of prostate biopsies. Towards this objective, we have identified 12 novel markers that are methylated in prostate cancer. We also developed detection assays using quantitative PCR and termination-coupled linear amplification (TCLA). TCLA offers improved sensitivity and specificity when applied to DNA from limited sources such as circulating DNA. A PCA test based on the analysis of methylated markers should reduce the number of repeat biopsies by at least 50% and is commercially valuable as an additional tool to improve prostate cancer diagnosis. In this prospective study, we propose to analyze the methylation ofthe panel of markers in urine DNA from patients with elevated PSA. If we successfully detect prostate cancer with 85% sensitivity and specificity, we will undertake a large validation study during Phase II in preparation for a clinical trial. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Over one million prostate biopsies are performed each year in the US on men with elevated PSA leading to the diagnosis of about 180,000 cases of prostate cancer. The majority of the biopsies are performed onmen who do not suffer from cancer. The aim of this study is to develop a diagnostic test that can detect molecular markers associated with prostate cancer in urine DNA in order to reduce the number of unnecessary biopsies.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government